Icon

PROSCAR (nda020180)- (5MG)

FINASTERIDE ORGANON
5MG
Yes No
2018-Oct-23 Expired
None None
None No
PROSCAR, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: • Improve symptoms • Reduce the risk of acute urinary retention • Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy.
8 0 8
Total Other Developers 5
Drugs with Suitability No
5MG ** ** - - 6
NDA Sales Available Total Generic Sales Available
Yes 7
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ** ****** **** *** **. *****'* ************ ******* *********** ****** **. **, ** ****, ** **** & ** ****, ********** ******* *** ******, *******-********** ********,, *******-**********, ********* ******, ***** (***) ***
****** **** ***** ******** *.*.*. *********** ****** ****** ********** **, ******, *****, ******* (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ********* ****** ****** **** ******* *********** **** ***, **** **. **-***, ****-**, ***, **********, *********, ********* ******, ***** (***) ***
****** ***** ****** *** *** ***** ************ ******* *********** ****** **. ***, *** *** ***, ******* ***** *. *. **. ** *******-*******, ******-****** *********, *********, ******* ******, ***** (***) ***
****** ****** **** *** *** ****** **** ******* *********** **** ***, **** **. **-***, ****-**, ***, **********, *********, ********* ******, ***** (***) ***
****** ****** **** *** *** ******* ***************, *** *********** * **** ***., *********, *** **** (**) *****, ****** ****** (***) ***
****** ****** **** *** *** ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** ****** **** *** *** ******* ***************, *** *********** *** * ******** *****, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** ****** **** *** *** ****** **** ******* *********** **** *, **. **.: ***, ***, *** & ***, ***** *********** ***, ********* *******, ************, ********* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. * ** **, *******, **** ******* ******, *******-***** *******, **. *-*, ****** ******, *********, ******* ******, ***** (***) ***
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** ***** **** *** ***** ************ ******* *********** ****** ** ****, ****, ****, **** ******* *****, ****** ********, *****, ******** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.